NASDAQ:AVGR Avinger (AVGR) Stock Forecast, Price & News $0.56 -0.01 (-1.67%) (As of 03:08 PM ET) Add Compare Share Share Today's Range$0.55▼$0.5850-Day Range$0.43▼$0.8252-Week Range$0.42▼$1.95Volume15,142 shsAverage Volume171,279 shsMarket Capitalization$5.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Avinger MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 5 Articles This WeekInsider TradingSelling Shares$181 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.21) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.50 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avinger. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.97% of the float of Avinger has been sold short.Short Interest Ratio / Days to CoverAvinger has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avinger has recently decreased by 48.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvinger does not currently pay a dividend.Dividend GrowthAvinger does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVGR. Previous Next 1.9 News and Social Media Coverage News SentimentAvinger has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Avinger this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AVGR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Avinger to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avinger insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $181.00 in company stock.Percentage Held by InsidersOnly 0.49% of the stock of Avinger is held by insiders.Percentage Held by InstitutionsOnly 14.14% of the stock of Avinger is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avinger are expected to grow in the coming year, from ($1.21) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avinger is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avinger is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvinger has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avinger (NASDAQ:AVGR) StockAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.Read More Receive AVGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avinger and its competitors with MarketBeat's FREE daily newsletter. Email Address AVGR Stock News HeadlinesJune 7, 2023 | finanznachrichten.deAvinger, Inc.: Avinger Receives 510(k) Clearance for Pantheris LV Image-Guided Atherectomy SystemJune 7, 2023 | finance.yahoo.comAvinger Receives 510(k) Clearance for Pantheris LV Image-Guided Atherectomy SystemJune 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 5, 2023 | finanznachrichten.deAvinger, Inc.: Avinger Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing DeviceJune 5, 2023 | finance.yahoo.comAvinger Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion (CTO) Crossing DeviceJune 5, 2023 | americanbankingnews.comAvinger (NASDAQ:AVGR) Coverage Initiated at StockNews.comMay 27, 2023 | americanbankingnews.comAvinger (NASDAQ:AVGR) Coverage Initiated by Analysts at StockNews.comMay 12, 2023 | morningstar.comAvinger Inc AVGR Stock QuoteJune 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 12, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Avinger (NASDAQ:AVGR)May 10, 2023 | finanznachrichten.deAvinger, Inc.: Avinger Reports First Quarter 2023 ResultsMay 10, 2023 | apnews.comAvinger: Q1 Earnings SnapshotMay 10, 2023 | finance.yahoo.comAvinger Reports First Quarter 2023 ResultsMay 4, 2023 | americanbankingnews.comAlphatec (NASDAQ:ATEC) vs. Avinger (NASDAQ:AVGR) Financial AnalysisMay 2, 2023 | finance.yahoo.comAvinger to Announce First Quarter 2023 Results on May 10April 28, 2023 | finance.yahoo.comLeading Data on the Treatment of In-Stent Restenosis with Pantheris Presented at Charing Cross International SymposiumApril 26, 2023 | finance.yahoo.comAvinger Receives 510(k) Clearance for Tigereye ST Image-Guided CTO Crossing SystemApril 26, 2023 | americanbankingnews.comAvinger (NASDAQ:AVGR) Now Covered by StockNews.comApril 25, 2023 | americanbankingnews.comAvinger (NASDAQ:AVGR) Now Covered by Analysts at StockNews.comApril 21, 2023 | americanbankingnews.comAvinger (NASDAQ:AVGR) Coverage Initiated by Analysts at HC WainwrightApril 17, 2023 | americanbankingnews.comAvinger (NASDAQ:AVGR) Receives New Coverage from Analysts at StockNews.comApril 2, 2023 | americanbankingnews.comAvinger, Inc. (NASDAQ:AVGR) Sees Significant Growth in Short InterestMarch 15, 2023 | finance.yahoo.comAvinger Reports Fourth Quarter 2022 ResultsMarch 2, 2023 | finance.yahoo.comAvinger to Announce Fourth Quarter 2022 Results on March 15February 4, 2023 | msn.comDogged determination makes SDSU’s Asia Avinger a ‘pest’ — and one of the bestJanuary 11, 2023 | finance.yahoo.comAvinger Announces 510(k) Filing of Pantheris LVNovember 12, 2022 | finance.yahoo.comAvinger Third Quarter 2022 Earnings: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)See More Headlines AVGR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVGR Company Calendar Last Earnings3/15/2023Today6/08/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVGR CUSIPN/A CIK1506928 Webwww.avinger.com Phone(650) 241-7900Fax800-229-2696Employees71Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,620,000.00 Net Margins-207.02% Pretax Margin-207.02% Return on Equity-530.21% Return on Assets-68.66% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.60 Sales & Book Value Annual Sales$8.27 million Price / Sales0.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book1.01Miscellaneous Outstanding Shares10,687,000Free Float10,635,000Market Cap$6.02 million OptionableNot Optionable Beta1.47 Key ExecutivesMr. Jeffrey M. Soinski (Age 61)Pres, CEO & Director Comp: $605.15kMr. Nabeel P. Subainati (Age 39)VP of Fin., Principal Financial Officer & Accounting Officer Comp: $295.85kMr. Himanshu N. Patel (Age 63)Chief Technology Officer Comp: $423.09kMr. Keith SchaeferChief Operating OfficerKey CompetitorsSeqLLNASDAQ:SQLSynaptogenixNASDAQ:SNPXNeuBase TherapeuticsNASDAQ:NBSEIntegrity ApplicationsNASDAQ:IGAPAytu BioPharmaNASDAQ:AYTUView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 252,136 shares on 5/16/2023Ownership: 4.379%Nabeel Paul SubainatiSold 223 sharesTotal: $180.63 ($0.81/share)View All Insider TransactionsView All Institutional Transactions AVGR Stock - Frequently Asked Questions Should I buy or sell Avinger stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares. View AVGR analyst ratings or view top-rated stocks. How have AVGR shares performed in 2023? Avinger's stock was trading at $1.0850 at the beginning of 2023. Since then, AVGR shares have decreased by 48.1% and is now trading at $0.5630. View the best growth stocks for 2023 here. Are investors shorting Avinger? Avinger saw a drop in short interest in May. As of May 15th, there was short interest totaling 317,000 shares, a drop of 48.6% from the April 30th total of 616,600 shares. Based on an average daily trading volume, of 241,400 shares, the days-to-cover ratio is currently 1.3 days. Approximately 3.0% of the company's stock are short sold. View Avinger's Short Interest. When is Avinger's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our AVGR earnings forecast. How were Avinger's earnings last quarter? Avinger, Inc. (NASDAQ:AVGR) released its earnings results on Wednesday, March, 15th. The medical device company reported ($0.70) earnings per share for the quarter. The medical device company had revenue of $2 million for the quarter. Avinger had a negative net margin of 207.02% and a negative trailing twelve-month return on equity of 530.21%. When did Avinger's stock split? Shares of Avinger reverse split before market open on Tuesday, March 15th 2022. The 1-20 reverse split was announced on Tuesday, March 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Avinger own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Organigram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM). When did Avinger IPO? (AVGR) raised $60 million in an initial public offering on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company acted as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers. What is Avinger's stock symbol? Avinger trades on the NASDAQ under the ticker symbol "AVGR." Who are Avinger's major shareholders? Avinger's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.38%). Insiders that own company stock include Himanshu Patel, James Cullen, Jeffrey M Soinski, Mark Weinswig and Nabeel Paul Subainati. View institutional ownership trends. How do I buy shares of Avinger? Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avinger's stock price today? One share of AVGR stock can currently be purchased for approximately $0.56. How much money does Avinger make? Avinger (NASDAQ:AVGR) has a market capitalization of $6.02 million and generates $8.27 million in revenue each year. The medical device company earns $-17,620,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis. How can I contact Avinger? Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.avinger.com. The medical device company can be reached via phone at (650) 241-7900, via email at info@dawson3d.com, or via fax at 800-229-2696. This page (NASDAQ:AVGR) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.